Beta Bionics, Inc.
NASDAQ:BBNXMedical - Equipment & Services
+$0.42 today
- Market cap
- $644.70M
- Beta
- 3.39
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$1.50
Volume 1.38M
Average 0.99M
BBNX Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Beta Bionics, Inc.NASDAQ: BBNX
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow declines year over year
Q1 FY2026 financing cash flow of $623K fell 99.7% year over year, behind the -98.4% change in trailing-twelve-month financing cash flow. Sequentially, it fell 41.2% from the prior quarter. Over 3 fiscal years it compounded at +55.8% a year.
Context
- Financing cash flow amounted to 214.3% of revenue in FY2025, up 128.9 pp from a year earlier.
- Financing cash flow increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -99.7% toward the trailing-twelve-month pace of -98.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 214.87M USD
- Year-over-year change
- +286.4%
- 3-year CAGR
- +55.8%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 214.87M | +286.4% |
| FY2024 | 2024-12-31 | 55.62M | -45.0% |
| FY2023 | 2023-12-31 | 101.03M | +77.9% |
| FY2022 | 2022-12-31 | 56.78M | — |
Financing Cash Flow vs competitors
How BBNX compares with its peers on the latest reported figures
- Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -98.4% is the lowest of 7, against a peer median of +265.4%.
- Financing cash flow amounts to 4.0% of revenue for BBNX, versus a peer median of 25.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | DKK 24.19B DKK | +8.3% | -18.1% | 7.3% | |
| LTM Jun 2026 | $2.33B USD | +220.3% | +45.1% | 46.9% | |
| LTM Jun 2026 | $845.4M USD | +971.5% | +145.4% | 27.7% | |
MMEDMiniMed Group, Inc. Common Stock | LTM Jul 2026 | $514M USD | — | +57.0% | 16.0% |
| LTM Mar 2026 | $278.74M USD | +310.5% | +145.1% | 77.3% | |
| LTM Mar 2026 | $235.48M USD | +2476.9% | — | 22.9% | |
| LTM Mar 2026 | $15.14M USD | -54.2% | — | — | |
| LTM Mar 2026 | $4.38M USD | -98.4% | +55.8% | 4.0% | |
| Peer median (excluding BBNX) | — | +265.4% | +57.0% | 25.3% | |
Competitors are the stored peer set for BBNX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Net Income | (64.75M) | (44.1M) | (54.76M) | (73.2M) |
| Depreciation & Amortization | 2.09M | 2.09M | 2.28M | 2.88M |
| Deferred Income Tax | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 6.1M | 5.66M | 6.38M | 16.38M |
| Change in Working Capital | (2.79M) | (6.36M) | (12.15M) | (8.99M) |
| Accounts Receivables | 0 | (4.49M) | (7.62M) | (5.16M) |
| Inventory | 0 | (1.19M) | (11.44M) | (9.88M) |
| Accounts Payables | (77K) | 716K | 1.52M | 2.1M |
| Other Working Capital | (2.71M) | (682K) | 5.39M | 3.95M |
| Other Non-Cash Items | (854K) | 10.27M | 9.96M | 12.01M |
| Operating Cash Flow | (60.21M) | (32.45M) | (48.27M) | (50.93M) |
| Capital Expenditures | (772K) | (402K) | (3.4M) | (5.3M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (69.3M) | (72.13M) | (327.51M) |
| Sales of Investments | 0 | 0 | 72M | 170M |
| Other Investing Activities | 3K | (69.29M) | 50K | 0 |
| Investing Cash Flow | (769K) | (69.69M) | (3.48M) | (162.81M) |
| Debt Repayment | 0 | 0 | 0 | 0 |
| Common Stock Issued | 389K | 29K | 55.62M | 214.87M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | 389K | 101.03M | 0 | 0 |
| Financing Cash Flow | 56.78M | 101.03M | 55.62M | 214.87M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 |
| Net Change in Cash | (4.2M) | (1.11M) | 3.87M | 1.14M |
| Free Cash Flow | (60.98M) | (32.85M) | (51.67M) | (56.22M) |
Beta Bionics, Inc.
NASDAQ:BBNX
Intrinsic Alpha fair value
Locked
Current Price
$14.33
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.